EU Clinical Trial 2017-002365-22

Open-label, single administration, ascending dose study to explore the safety and efficacy of a gene therapy with a unilateral subretinal administration of HORA RLBP1 in patients with a retinal dystrophy harbouring biallelic mutations in the RLBP1 gene leading to a defect in CRALBP expression  Feb 15, 2019

Main objective of the trial: To assess the safety of a unilateral subretinal administration of HORA RLBP1

Parties

Sponsors

JSON preview

Similar records

Title

Source:  EMA Last updated:  May 30, 2019

From ClinicalTrialsRegister.eu, a database of the European Medicines Agency. This record may not reflect the most current and accurate data available from the EMA.